IVIg therapy increases delivery birthweight in babies born to women with elevated preconception proportion of peripheral blood (CD56+/CD3-) natural killer cells.

CONCLUSION: In women with elevated preconception peripheral NK cells, mean birthweight at delivery is low without IVIg therapy ±2,654 ± 627 grams) but significantly improved with IVIg therapy ±3,267 ± 373 grams). In high risk wom without preconception NK cell elevation, mean birthweight at delivery is not further-increased with IVIg therapy ±3,202 ± 357 grams with IVIg vs.±3,129 ± 527 grams without IVIg). IVIg may be a treatment option for women with preconception NK elevation at risk of a low birthweight baby. Preconception immune testing may be a tool for determining which patients will benefit from IVIg therapy. Larger repeat studies are needed for confirmation. PMID: 29949278 [PubMed - in process]
Source: Clinical and Experimental Obstetrics and Gynecology - Category: OBGYN Tags: Clin Exp Obstet Gynecol Source Type: research